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Inhibition of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) or 
glycogen synthase kinase-3β (GSK-3β) is estimated to be the central therapeutic 
approach for Alzheimer’s disease (AD). In this study, water extract of Kangen-
karyu, its crude drug and chemical composition used in oriental medicine 
were evaluated regarding their BACE1 and GSK-3β inhibitory activities. 
Fluorescence resonance energy transfer was used to characterize the BACE1 
inhibitory effect of Kangen-karyu, its crude drug and chemical composition. 
GSK-3β activity was determined using the Kinase-Glo Luminescent Kinase 
Assay Platform. The water extract of Kangen-karyu inhibited BACE1 and 
GSK-3β in concentration-dependent manners when compared with reference 
drugs, quercetin and luteolin. Among six components of Kangen-karyu, the 
water extracts of Salviae Miltiorrhizae Radix or Cyperi Rhizoma exhibited 
significant inhibitory effects on BACE1 and GSK-3β. Among the constituents 
of Salviae Miltiorrhizae Radix extract, salvianolic acid C, salvianolic acid 
A, rosmarinic acid, and magnesium lithospermate B significantly inhibited 
BACE1. In addition, they inhibited GSK-3β with an IC50 value range of 6.97 to 
135.35 μM. From these results, one of the effectiveness and its mechanisms of 
action of Kangen-karyu against AD may be the inhibition of BACE1 and GSK-
3β, and one of the active ingredients of Kangen-karyu is Salviae Miltiorrhizae 
Radix and its constituents.
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1. Introduction
Alzheimer’s disease (AD) is the most prevalent 
neurodegenerative dementia with two major pathological 
features: extra- and intracellular amyloid plaques 
and intraneuronal neurofibrillary tangles formed of 
amyloid β-protein (Aβ) and phosphorylated tau protein, 
respectively [1]. Aβ toxicity is believed to play a major 
role in the pathogenesis of AD [2]. For that reason, anti-
amyloid strategies have been a major focus of AD drug 
development.
Aβ is a cleavage product of amyloid precursor protein 
(APP) by two proteases: β-site APP cleaving enzyme 
1 (BACE1) and the γ-secretase complex. APP is firstly 
cleaved by BACE1, producing secreted APP-β and a 
C-terminal fragment (CTF) known as β-CTF. β-CTF 
is subsequently cleaved by γ-secretase to release Aβ 
[3]. BACE1 is a rate-limiting enzyme for Aβ generation 
and is considered one of the major therapeutic targets 
for AD [4]. However, the increased production of Aβ 
peptides derived from APP via the sequential proteolytic 
cleavages catalyzed by BACE1, has a controversial link 
to the glycogen synthase kinase 3 (GSK-3) enzyme. In 
AD, GSK-3β is responsible for the phosphorylation of 
microtubule-related tau protein, which affects microtubule 
stability and delocalization of the abnormal tau protein 
to brain cells and dendrites [5]. Due to the aggregation 
of hyperphosphorylated tau proteins, neurofibrillary 
tangles form, and trigger synaptic dysfunction and 
neuronal apoptosis, which lead to cognitive impairment 
[6]. Inhibition of BACE1 or GSK-3β is considered as the 
central therapeutic approach against AD.
Traditional Chinese medicine has been widely used in 
China for thousands of years. Traditional Chinese medicine 
has now established its position in the Western world, and 
has become a prime source of drug discovery. Kangen-
karyu, which consists of six medicinal herbs, has attracted 
considerable attention due to their biological activities 
and potential health benefit effects: Salviae Miltiorrhizae 
Radix, Cnidii Rhizoma, Paeoniae Radix, Carthami Flos, 
Aucklandiae Radix, and Cyperi Rhizoma (Table 1). Kangen-
karyu is a traditional herbal formula slightly modified the 
composition of Chinese prescription (Guan-xin No.2) that 
has been used to treat blood circulation-related various 
symptoms, neuro-degenerative disorders, diabetes, and 
diabetic complications. The recent clinical trials have 
reported the potential clinical applications of using Kangen-
karyu extract, such as for cognitive dysfunctions in type 2 
diabetes symptoms trough improving central cholinergic 
dysfunction [7], age-related memory deficit by normalizing 
neuroplasticity-associated neuronal signaling system, and 
the VEGF signaling system in the brain [8] against oxidative 
stress mediated tissue injury [9], type 1 and type 2 diabetes 
and diabetic complications [10,11], a neuroprotective effect [12]. 
However, there are as yet no reports of BACE1 and GSK-3β, 
regarded as the central therapeutic approach against AD.
Table 1. Composition of Kangen-karyu.
Common name Botanical name Family name
Salviae Miltiorrhizae  
Radix
Salvia miltiorrhiza  
BUNGE
Labiatae
Cnidii Rhizoma Cnidium officinale MAKINO Umbelliferae
  Paeoniae Radix Paeonia lactiflora PALLAS Paeoniaceae
  Carthami Flos Carthamus tinctorius L. Compositae
  Aucklandiae Radix Aucklandia lappa DCNE. Compositae
  Cyperi Rhizoma Cyperus rotundus L. Cyperaceae
Therefore, we present the performance evaluation 
for the in vitro BACE1 and GSK-3β inhibition potential 
of water extract of Kangen-karyu, its crude drug and 
chemical composition.
2. BACE1 Inhibition
We performed a comparative study on BACE1 
inhibition with a boiled water extract of Kangen-karyu 
and its components. As shown in Table 2, the boiled 
water extract of Kangen-karyu demonstrated moderate 
inhibition. Among the components, moderate inhibition 
was also observed with a boiled water extract of Salviae 
Miltiorrhizae Radix and Cyperi Rhizoma followed by 
mild inhibition by Cnidii Rhizoma, Paeoniae Radix, and 
Carthami Flos. No inhibition was observed with a boiled 
water extract of Aucklandiae Radix.
Table 2. BACE1 inhibitory potentials of water extract of 
Kangen-karyu and its constituents.
   Sample IC50 values
a
   Kangen-karyu 77.40 ± 4.58
   Salviae Miltiorrhizae Radix 89.84 ± 1.87
   Cnidii Rhizoma 147.09 ± 0.93
   Paeoniae Radix 143.57 ± 1.79
   Carthami Flos 233.34 ± 0.05
   Aucklandiae Radix >400
   Cyperi Rhizoma 91.16 ± 2.21
   Quercetinb 10.49 ± 0.28*
aThe 50% inhibitory concentrations (IC50, μg/mL) are expressed 
as the mean ± SED. bUsed as positive control. 
*Values are expressed in μM.
Furthermore, we studied the compositions of Salviae 
Miltiorrhizae Radix (Figure 1). Among the six compounds 
tested, salvianolic acid C exhibited significant inhibition 
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of BACE1 with an IC50 value of 9.18 ± 0.03 μM, while 
IC50 of the positive control quercetin was 10.49 ± 0.54 
μM, as shown in Table 3. Likewise, salvianolic acid A 
exhibited similar maximum inhibition of BACE1 with 
marked IC50 inhibitory activity, but salvianolic acid B and 
caffeic acid showed weak inhibitory activities against 
BACE1. Rosmarinic acid and magnesium lithospermate B 
displayed moderate to mild activity against BACE1.
Table 3. BACE1 inhibitory potentials of compounds 
identified in Salviae Miltiorrhizae Radix.
Sample IC50 values
a
  Salvianolic acid A 13.01 ± 0.32
  Salvianolic acid B 168.90 ± 0.70
  Salvianolic acid C 9.18 ± 0.03
  Caffeic acid >200
  Rosmarinic acid 29.77 ± 0.70
  Magnesium lithospermate B 30.35 ± 2.67
Quercetinb 10.49 ± 0.54
aThe 50% inhibitory concentrations (IC50, μM) are expressed as 
the mean ± SEM. bUsed as positive control.
3. GSK-3β Inhibition
As shown in Table 4, the boiled water extract of 
Kangen-karyu potently suppressed GSK-3β with an 
IC50 value of 17.05 ± 1.14 μg/mL. All components of 
the boiled water extract of Kangen-karyu’s individual 
components showed potent suppression against GSK-3β 
with IC50 values ranging from 7.77 to 93.61 μg/mL. The 
extract of Salviae Miltiorrhizae Radix (IC50: 7.77 ± 1.38 
μg/mL) was the most potent among them, followed by 
Cyperi Rhizoma (IC50: 20.68 ± 2.50 μg/mL). The extracts 
of other herbal components showed weak and moderate 
inhibitory activity in GSK-3β assays.
Table 4. GSK-3β inhibitory potentials of water extract of 
Kangen-karyu and its constituents.
Sample IC50 values
a
   Kangen-karyu 17.05 ± 1.14
   Salviae Miltiorrhizae Radix 7.77 ± 1.38
   Cnidii Rhizoma 66.74 ± 2.05
   Paeoniae Radix 62.51 ± 1.89
   Carthami Flos 93.61 ± 3.99
   Aucklandiae Radix 85.04 ± 6.32
   Cyperi Rhizoma 20.68 ± 2.50
   Luteolinb 2.18 ± 0.13*
aThe 50% inhibitory concentrations (IC50, μg/mL) are expressed 
as the mean ± SED. bUsed as positive control. 
*Values are expressed in μM.
Next, we evaluated the constituent compounds of 
Salviae Miltiorrhizae Radix which showed excellent 
GSK inhibitory effect. As listed in Table 5, magnesium 
lithospermate B, salvianolic acid A, salvianolic acid 
B, and salvianolic acid C displayed strong inhibition 
against GSK-3β. Especially, salvianolic acid B was the 
most effective, inhibiting the enzyme by 50% at 6.97 ± 
0.96 μM. Magnesium lithospermate B, salvianolic acid 
Figure 1. Chemical structures of active compounds from S. miltiorrhiza.
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A, and salvianolic acid C showed roughly one-fifth the 
activity of salvianolic acid B with similar IC50 values of 
approximately 30 μM. On the other hand, rosmarinic acid 
(IC50: 135.35 ± 4.69 μM) and caffeic acid (IC50: 425.01 ± 
7.61 μM) showed moderate or mild inhibitory activity in 
GSK-3β assays.
Table 5. GSK-3β inhibitory potentials of compounds 
identified in Salviae Miltiorrhizae Radix.
Sample IC50 values
a
  Salvianolic acid A 30.21 ± 3.14
  Salvianolic acid B 6.97 ± 0.96
  Salvianolic acid C 31.82 ± 2.08
  Caffeic acid 425.01 ± 7.61
  Rosmarinic acid 135.35 ± 4.69
  Magnesium lithospermate B 33.07 ± 3.88
  Luteolinb 2.18 ± 0.13
aThe 50% inhibitory concentrations (IC50, μM) are expressed as 
the mean ± SEM. bUsed as positive control.
4. Discussion
Under pathological patterns, the permitted ongoing 
treatment approaches for AD are acetylcholinesterase 
inhibitors (AChEIs: donepezil, galanthamine, and 
rivastigmine, all enhancing acetylcholine levels) and 
the non-competitive/low affinity N-methyl-D-aspartate 
receptor antagonist (NMDA antagonist: memantine, 
activating glutamate neurotransmission) [13]. However, 
these types of drugs only provide the effect of delaying 
or relieving symptoms. Since AChEIs (cholinergic) and 
memantine (glutamatergic) target two different aspects 
of AD pathology, combination treatment is beneficial 
effective in patients with moderate to severe AD, by 
comparison with the monotherapy [14]. Furthermore, 
discovery of different targets that are decisive importance 
in promoting AD pathogenesis is the current main focus. 
Currently, it has been hypothesized that BACE1 and GSK-
3β contribute distinctly to suppressing the development of 
AD as a linking bridge between Aβ and tau protein.
A number of recent studies demonstrated a correlation 
between AD and oxidative stress [15-17]. Specifically, AD 
may be associated with cellular oxidative stress including 
augmentation of protein oxidation, protein nitration, 
glycoloxidation, and lipid peroxidation as well as the 
accumulation of Aβ [15,17,18]. In general, oxidative stress 
involves the production of superoxide (O2
-), and the 
formation of nitrotyrosine and peroxynitrite (ONOO-
) derived from nitric oxide (NO), all of which are 
destructive free radical oxidants [19]. Therefore, drugs that 
are effective against all destructive free radical oxidants 
may by important therapies for AD [20-23]. Simultaneous 
inhibition of nitrotyrosine and ONOO- along with BACE1 
and GSK-3β may represent a promising avenue of 
research for the development of anti-AD agents.
In a previous study, we reported that Kangen-karyu 
inhibited reactive oxygen species (ROS) production in the 
presence of high glucose-induced oxidative stress using 
LLC-PK1 cells, renal tubular cells, which are the most 
vulnerable renal tissue to oxidative stress. The intracellular 
ROS (O2
-, NO, and ONOO-) induced by high glucose was 
concentration-dependently inhibited by Kangen-karyu 
treatment. Kangen-karyu also reduced the overexpression 
of inducible nitric oxide synthase, cyclooxygenase-2 
proteins induced by high glucose. Furthermore, treatment 
with Kangen-karyu inhibited the nuclear translocation of 
nuclear factor-kappa B [24]. Moreover, Kangen-karyu had 
a pleiotropic effect on several oxidative stress-related 
parameters and exerted a renoprotective effect on the 
development of diabetic nephropathy in type 2 diabetic 
db/db mice [11]. These findings indicate that Kangen-
karyu is a potential therapeutic agent that will reduce 
the damage caused by hyperglycemia-induced oxidative 
stress associated with diabetes. In addition, Kangen-karyu 
might prevent AD by attenuating the increased oxidative 
biomarkers, including the generation of ROS.
In the present study, we investigated the anti-AD 
potential of Kangen-karyu and its components using 
BACE1 and GSK-3β inhibitory assays. Based on the 
results shown in Tables 2 and 4, the water extract 
of Kangen-karyu shows inhibitory potential against 
BACE1, as well as GSK-3β. Among the six components, 
Salviae Miltiorrhizae Radix and Cyperi Rhizoma 
showed moderate inhibition of BACE1, while Salviae 
Miltiorrhizae Radix exhibited stronger inhibitory activity. 
In contrast, Cnidii Rhizoma, Paeoniae Radix, Carthami 
Flos, and Aucklandiae Radix showed weak inhibitory 
activity against BACE1 and GSK-3β. Focusing on GSK-
3β inhibition, Salviae Miltiorrhizae Radix was about 2.7 
times more active than Cyperi Rhizoma and, thus, was 
selected for further study. Therefore, we estimated the 
potentials of those chemical composition from the active 
water extract of Salviae Miltiorrhizae Radix. 
Phytochemical constituents of Salviae Miltiorrhizae 
Radix have been extensively studied. Water-soluble 
fraction of Salviae Miltiorrhizae Radix contains 
caffeic acid and its derivatives such as rosmarinic acid 
(dimer), salvianolic acid A (trimer), salvianolic acid B 
(tetramer), salvianolic acid C (trimer), and magnesium 
lithospermate B (tetramer). Chief of all, salvianolic acids 
are the principal water-soluble ingredients in Salviae 
Miltiorrhizae Radix, among which salvianolic acid A 
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(caffeic acid trimer) and salvianolic acid B (caffeic acid 
tetramer) are the most abundant phytochemicals [25-27]. A 
review of the BACE1 and GSK-3β inhibitory activities 
of our evaluated compounds showed that a monomeric 
caffeic acid showed weak activity while its dimer, trimer, 
and tetramer displayed a significant increase in activity. 
Especially, it exhibited remarkable activity in trimers 
and tetramers rather than dimers. This pattern means that 
the activity is enhanced when caffeic acid is condensed. 
Simultaneous inhibition of both BACE1 and GSK-3β may 
provide efficient benefits in the treatment of AD.
In the present study, we evaluated the anti-AD activity 
of Kangen-karyu and its invididual ingredients via 
BACE1 and GSK-3β assays. The results demonstrated 
that Salviae Miltiorrhizae  Radix is the main active 
component of Kangen-karyu against the two enzymes. 
Furthermore, rosmarinic acid derivatives were found to 
be marked inhibitors. Among them, salvianolic acid C 
was a potent mixed inhibitor of BACE1 and showed the 
lowest IC50 value (9.18 ± 0.03 μM), while salvianolic acid 
B exhibited the highest inhibitory activity against GSK-
3β with an IC50 value of 6.97 ± 0.96 μM. Therefore, one 
of the mechanisms of action of Kangen-karyu against 
AD may be the inhibition of BACE1 and GSK-3β, and 
one of the active components of Kangen-karyu is Salviae 
Miltiorrhize Radix and its constituents, salvianolic acids 
C and B.
5. Conclusions
Alzheimer’s disease drugs generally developed as a 
single target strategy are not only unsatisfactory for AD 
treatment, but also have several side effects. Therefore, 
as a potential effective strategy in the treatment of AD, 
the choice of the multi-target strategy has been proposed. 
Therefore, Kangen-karyu and its herbal formula (Salviae 
Miltiorrhizae Radix) containing caffeic acid derivatives 
with both BACE1 and GSK-3β inhibitory activities could 
be a promising herbal medicine for the treatment drug of 
cognition deficit disorders, such as AD-type dementia.
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